Clinical Study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study Of Arn-509 In Men With Non-Metastatic (M0) Castration-Resistant Prostate

Posted Date: May 15, 2019

  • Investigator: R. Bruce Bracken
  • Specialties:
  • Type of Study: Drug

The main purpose of this research study is to determine whether ARN-509 is safe and effective when compared to placebo (inactive substance) in delaying the development of metastases in prostate cancer patients with rising PSA.

Criteria:

To Be Eligible For The Study You Must Have Prostate Cancer That Is At High Risk Of Progressing And S

Keywords:

Arn-509-003, Cancer, Castration-Resistant, Non-Metastatic , Prostate

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.